
    
      This is an intrapatient dose-escalation study. Three dose levels of mavorixafor will be
      explored: 200 milligrams (mg) once daily (QD) (dose level 1), 400 mg QD (dose level 2), and
      600 mg QD (dose level 3). Ibrutinib will be administered at its labeled dose for participants
      with WM, 420 mg orally QD. Each treatment cycle will be 28 days.
    
  